Advances in oncologic imaging

Imaging has become a pivotal component throughout a patient's encounter with cancer, from initial disease detection and characterization through treatment response assessment and posttreatment follow‐up. Recent progress in imaging technology has presented new opportunities for improving clinical care. This article provides updates on the latest approaches to imaging of 5 common cancers: breast, lung, prostate, and colorectal cancers, and lymphoma. CA Cancer J Clin 2012. © 2012 American Cancer Society.

[1]  M. Jeffery,et al.  Follow-up strategies for patients treated for non-metastatic colorectal cancer. , 2016, The Cochrane database of systematic reviews.

[2]  D. Penson.  Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. , 2013, The Journal of urology.

[3]  Steven P. Larson,et al.  Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer , 2012, Cancer.

[4]  B. Durbin-Johnson,et al.  Active surveillance for prostate cancer compared with immediate treatment , 2012, Cancer.

[5]  John Kurhanewicz,et al.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer , 2012, BJU international.

[6]  M. Kattan,et al.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer , 2012, BJU international.

[7]  Etta D Pisano,et al.  Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. , 2012, JAMA.

[8]  T. Nagaoka,et al.  Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. , 2012, Radiology.

[9]  M. Weiser,et al.  Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer , 2012, European Radiology.

[10]  F. O'Malley,et al.  Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Zelenetz,et al.  Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. , 2012, Blood.

[12]  L. Gordon,et al.  High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database , 2012, Leukemia & lymphoma.

[13]  Tae Hyun Kim,et al.  Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer. , 2012, International journal of radiation oncology, biology, physics.

[14]  S. Ramsey,et al.  Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  P. T. Phang,et al.  Accuracy of Endorectal Ultrasound for Measurement of the Closest Predicted Radial Mesorectal Margin for Rectal Cancer , 2012, Diseases of the colon and rectum.

[16]  A. Oto,et al.  Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. , 2011, AJR. American journal of roentgenology.

[17]  D. Collins,et al.  Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. , 2011, Radiology.

[18]  H. Schöder,et al.  Six Cycles of ABVD and a Negative PET Scan Negates the Need for Radiologic Follow-up in Early Stage, Non-Bulky Hodgkin Lymphoma: MSKCC Retrospective Analysis , 2011 .

[19]  R. Figlin,et al.  18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib , 2011, The Journal of Nuclear Medicine.

[20]  Mithat Gönen,et al.  [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. , 2011, International journal of radiation oncology, biology, physics.

[21]  C. Sirlin,et al.  Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[23]  D. Groheux,et al.  The Yield of 18F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study , 2011, The Journal of Nuclear Medicine.

[24]  M. Cooperberg,et al.  UC San Francisco UC San Francisco Previously Published Works Title Active surveillance for prostate cancer : Progress and promise , 2011 .

[25]  Felix M Mottaghy,et al.  Whole-body diffusion-weighted magnetic resonance imaging: current evidence in oncology and potential role in colorectal cancer staging. , 2011, European journal of cancer.

[26]  Pek-Lan Khong,et al.  Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. , 2011, AJR. American journal of roentgenology.

[27]  M. Trněný,et al.  Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma , 2011, Leukemia & lymphoma.

[28]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.

[29]  S. Solomon,et al.  Radiofrequency ablation: treatment of primary lung cancer. , 2011, Seminars in roentgenology.

[30]  Andrew B Rosenkrantz,et al.  Role of MRI in minimally invasive focal ablative therapy for prostate cancer. , 2011, AJR. American journal of roentgenology.

[31]  S. Ciatto,et al.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. , 2011, Radiology.

[32]  J. Trachtenberg,et al.  Evolution from active surveillance to focal therapy in the management of prostate cancer. , 2011, Future oncology.

[33]  Yousef Mazaheri,et al.  Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. , 2011, Radiology.

[34]  A. Kawashima,et al.  The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide. , 2011, AJR. American journal of roentgenology.

[35]  J. Youk,et al.  The diagnosis of non-malignant papillary lesions of the breast: comparison of ultrasound-guided automated gun biopsy and vacuum-assisted removal. , 2011, Clinical radiology.

[36]  S. Larson,et al.  Developing imaging strategies for castration resistant prostate cancer , 2011, Acta oncologica.

[37]  Dan Stoianovici,et al.  Advancements in MR imaging of the prostate: from diagnosis to interventions. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[38]  M. Schwaiger,et al.  Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment , 2011, The Journal of Nuclear Medicine.

[39]  Lawrence H. Schwartz,et al.  Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results , 2011, European Radiology.

[40]  Steve Halligan,et al.  Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. , 2011, Radiology.

[41]  Jae Young Lee,et al.  Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer , 2011, European Radiology.

[42]  D. Cosgrove,et al.  Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100) , 2011, European Radiology.

[43]  Felix Diekmann,et al.  Evaluation of contrast-enhanced digital mammography. , 2011, European journal of radiology.

[44]  A. LaCasce,et al.  End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  B. Solomon,et al.  Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib , 2011, Clinical Cancer Research.

[46]  C. Klabunde,et al.  Adoption of CT colonography by US hospitals. , 2011, Journal of the American College of Radiology : JACR.

[47]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[48]  T. Leiner,et al.  Accuracy of Gadofosveset-enhanced MRI for Nodal Staging and Restaging in Rectal Cancer , 2011, Annals of surgery.

[49]  T. Takahara,et al.  Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. , 2011, AJR. American journal of roentgenology.

[50]  A. Soricelli,et al.  Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Serge Muller,et al.  Dual-energy contrast-enhanced digital mammography: initial clinical results , 2011, European Radiology.

[52]  A. Verbaeys,et al.  Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. , 2011, European journal of radiology.

[53]  Yousef Mazaheri,et al.  MRI of the prostate: Clinical relevance and emerging applications , 2011, Journal of magnetic resonance imaging : JMRI.

[54]  Baris Turkbey,et al.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.

[55]  H. Jadvar.  Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.

[56]  J. Humm,et al.  Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. , 2010, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  David H. Kim,et al.  CT colonography for combined colonic and extracolonic surveillance after curative resection of colorectal cancer. , 2010, Radiology.

[58]  S. Larson,et al.  18F-FDG PET/CT for the Prediction and Detection of Local Recurrence After Radiofrequency Ablation of Malignant Lung Lesions , 2010, The Journal of Nuclear Medicine.

[59]  J. Armitage,et al.  A decade of progress in lymphoma: advances and continuing challenges. , 2010, Clinical lymphoma, myeloma & leukemia.

[60]  K. Rosenzweig,et al.  ACR Appropriateness Criteria® noninvasive clinical staging of bronchogenic carcinoma. , 2010, Journal of thoracic imaging.

[61]  J. S. Júnior,et al.  18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma , 2010, The Journal of Nuclear Medicine.

[62]  Jessica B Robbins,et al.  Colorectal polyps: stand-alone performance of computer-aided detection in a large asymptomatic screening population. , 2010, Radiology.

[63]  A. D. Van den Abbeele,et al.  Surveillance imaging of Hodgkin lymphoma patients in first remission , 2010, Cancer.

[64]  C. Hassan,et al.  Performance improvements of imaging-based screening tests. , 2010, Best practice & research. Clinical gastroenterology.

[65]  David Gur,et al.  Digital breast tomosynthesis in the diagnostic environment: A subjective side-by-side review. , 2010, AJR. American journal of roentgenology.

[66]  L. Liberman,et al.  Breast MRI screening of women with a personal history of breast cancer. , 2010, AJR. American journal of roentgenology.

[67]  J. Szer,et al.  Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy , 2010, British journal of haematology.

[68]  Ying Yuan,et al.  Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. , 2010, AJR. American journal of roentgenology.

[69]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[70]  T. Nihashi,et al.  Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. , 2010, The oncologist.

[71]  Wendy B DeMartini,et al.  Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. , 2010, AJR. American journal of roentgenology.

[72]  M. Trněný,et al.  Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  M. Gönen,et al.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. , 2010, Journal of the American College of Surgeons.

[74]  A. Zelenetz,et al.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  P. Choyke,et al.  Imaging Prostate Cancer: An Update on Positron Emission Tomography and Magnetic Resonance Imaging , 2010, Current urology reports.

[76]  Perry J Pickhardt,et al.  Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults. , 2010, Radiology.

[77]  E. Hindié,et al.  18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[78]  Roberto Passariello,et al.  Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy , 2010, Clinical Cancer Research.

[79]  Kazuro Sugimura,et al.  Prostate cancer detection with 3 T MRI: Comparison of diffusion‐weighted imaging and dynamic contrast‐enhanced MRI in combination with T2‐weighted imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[80]  Myeong-Jin Kim,et al.  Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent , 2010, Journal of magnetic resonance imaging : JMRI.

[81]  David H. Kim,et al.  CT colonography: performance and program outcome measures in an older screening population. , 2010, Radiology.

[82]  V. Torri,et al.  Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysis , 2010, Journal of magnetic resonance imaging : JMRI.

[83]  Ora Israel,et al.  18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.

[84]  P. Scardino,et al.  Critical review of prostate cancer predictive tools. , 2009, Future oncology.

[85]  Myrna C B Godoy,et al.  Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. , 2009, Radiology.

[86]  R. Warren,et al.  Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  V. Diehl,et al.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  M. Choti,et al.  NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[89]  David Gur,et al.  Digital breast tomosynthesis: observer performance study. , 2009, AJR. American journal of roentgenology.

[90]  H. Jadvar.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET , 2009, Nature Reviews Urology.

[91]  R. Hicks,et al.  Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. , 2009, International journal of radiation oncology, biology, physics.

[92]  T. Nihashi,et al.  Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Katarzyna J Macura,et al.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. , 2009, Radiology.

[94]  A. Rahmouni,et al.  Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.

[95]  A. Crucitti,et al.  Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. , 2009, Radiology.

[96]  Jordi Rimola,et al.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.

[97]  Winfried Brenner,et al.  Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[99]  L. Rabeneck,et al.  Rates of New or Missed Colorectal Cancer After Barium Enema and Their Risk Factors: A Population-Based Study , 2008, The American Journal of Gastroenterology.

[100]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[101]  J. Millholland,et al.  A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection , 2008, The American Journal of Gastroenterology.

[102]  M. Gönen,et al.  The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  J. Leonard,et al.  Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  Julie R. Gralow,et al.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Michael J Fulham,et al.  PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study , 2008, Journal of Nuclear Medicine.

[106]  Robert J Myerson,et al.  Tumor Hypoxia Detected by Positron Emission Tomography with 60Cu-ATSM as a Predictor of Response and Survival in Patients Undergoing Neoadjuvant Chemoradiotherapy for Rectal Carcinoma: A Pilot Study , 2008, Diseases of the colon and rectum.

[107]  D. Regge,et al.  Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. , 2008, Clinical radiology.

[108]  F. Fazio,et al.  11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. , 2008, European urology.

[109]  Les Irwig,et al.  Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Jean B. Cormack,et al.  Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. , 2008, JAMA.

[111]  J. Hartley,et al.  Transanal endoscopic microsurgery in early rectal cancer: time for a trial? , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[112]  Perry J Pickhardt,et al.  Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis. , 2008, Archives of internal medicine.

[113]  Dow-Mu Koh,et al.  The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[114]  D. Rubello,et al.  PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[115]  H. Schöder,et al.  PET imaging for response assessment in lymphoma: potential and limitations. , 2008, Radiologic clinics of North America.

[116]  Bernadette Coles,et al.  The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? , 2008, Cancer.

[117]  R. Vierkant,et al.  Breast cancer risk in women with radial scars in benign breast biopsies , 2008, Breast Cancer Research and Treatment.

[118]  T. Nihashi,et al.  18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review , 2007, Journal of Nuclear Medicine.

[119]  Byung Kwan Park,et al.  Value of Diffusion-Weighted Imaging for the Prediction of Prostate Cancer Location at 3T Using a Phased-Array Coil: Preliminary Results , 2007, Investigative radiology.

[120]  H. Hricak,et al.  Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. , 2007, Radiology.

[121]  Hashim Uddin Ahmed,et al.  Will focal therapy become a standard of care for men with localized prostate cancer? , 2007, Nature Clinical Practice Oncology.

[122]  Tristan Barrett,et al.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. , 2007, AJR. American journal of roentgenology.

[123]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[124]  Robert E Lenkinski,et al.  Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. , 2007, Radiology.

[125]  Clare Allen,et al.  Dynamic contrast enhanced MRI in prostate cancer. , 2007, European journal of radiology.

[126]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  A. Levis,et al.  Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi , 2007, Annals of Hematology.

[128]  Simone Schrading,et al.  MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study , 2007, The Lancet.

[129]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[130]  C. Gatsonis,et al.  Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. , 2007, Radiology.

[131]  M. Kurrer,et al.  Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? , 2007, Radiology.

[132]  H. Zaidi,et al.  18F‐choline and/or 11C‐acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate‐specific antigen values (<1 ng/mL) after radical prostatectomy , 2007, BJU international.

[133]  G. Gerken,et al.  Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population , 2007, Gut.

[134]  Jin Mo Goo,et al.  Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[135]  Ralph T. Wynn,et al.  Underestimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. , 2007, AJR. American journal of roentgenology.

[136]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[137]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Takeo Ishigaki,et al.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. , 2007, European journal of radiology.

[139]  M. Rugge,et al.  The Potential of Restaging in the Prediction of Pathologic Response After Preoperative Chemoradiotherapy for Rectal Cancer , 2007, Annals of Surgical Oncology.

[140]  J. H. Kim,et al.  Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[141]  S. Cole,et al.  Comparison of a brush‐sampling fecal immunochemical test for hemoglobin with a sensitive guaiac‐based fecal occult blood test in detection of colorectal neoplasia , 2006, Cancer.

[142]  P. D. Peppercorn,et al.  Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study , 2006, BMJ : British Medical Journal.

[143]  L. Specht,et al.  Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake , 2006, Hematological oncology.

[144]  L. Guittet,et al.  Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population , 2006, Gut.

[145]  Deepa Narayanan,et al.  High‐Resolution Fluorodeoxyglucose Positron Emission Tomography with Compression (“Positron Emission Mammography”) is Highly Accurate in Depicting Primary Breast Cancer , 2006, The breast journal.

[146]  T. Nazeer,et al.  Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.

[147]  Wei Huang,et al.  Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. , 2006, Radiology.

[148]  A. Zelenetz,et al.  Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[149]  Charles J. Kahi,et al.  Guidelines for Colonoscopy Surveillance after Cancer Resection: A Consensus Update by the American Cancer Society and US Multi‐Society Task Force on Colorectal Cancer * † , 2006, CA: a cancer journal for clinicians.

[150]  R. Kodet,et al.  Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[151]  M. Kattan,et al.  Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. , 2006, Radiology.

[152]  S. Marnitz,et al.  Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy , 2006, Clinical Cancer Research.

[153]  Bruce D Minsky,et al.  Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  J Alfred Witjes,et al.  Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. , 2005, Radiology.

[156]  L. Liberman,et al.  Determination of the Presence and Extent of Pure Ductal Carcinoma in Situ by Mammography and Magnetic Resonance Imaging , 2005, The breast journal.

[157]  N. Hylton,et al.  Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: Results from the International Breast Magnetic Resonance Consortium (IBMC) trial , 2005, Journal of surgical oncology.

[158]  J. V. van Engelshoven,et al.  Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis. , 2005, Seminars in ultrasound, CT, and MR.

[159]  D. Dupuy,et al.  CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors. , 2005, AJR. American journal of roentgenology.

[160]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  J. Yee,et al.  CT colonography reporting and data system: a consensus proposal. , 2005, Radiology.

[162]  D. Panicek,et al.  Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. , 2005, Radiology.

[163]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[164]  C. Dence,et al.  Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[165]  D. Yee,et al.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. , 2004, Radiology.

[166]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[167]  Shijun Kang,et al.  Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumours , 2004, World journal of surgical oncology.

[168]  Thomas F Hany,et al.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.

[169]  M. Cooperberg,et al.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  L. Bonomo,et al.  Preoperative T and N staging of colorectal cancer: accuracy of contrast-enhanced multi-detector row CT colonography--initial experience. , 2004, Radiology.

[171]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[172]  B. Beuthien-Baumann,et al.  Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.

[173]  A. D. Van den Abbeele,et al.  FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison , 2004, Leukemia & lymphoma.

[174]  Robert B Livingston,et al.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[175]  C. Earle,et al.  Follow-up of patients with curatively resected colorectal cancer: a practice guideline , 2003, BMC Cancer.

[176]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  M. Tomas,et al.  18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[178]  P. Dupont,et al.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. , 2003, Blood.

[179]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[180]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[181]  Ning-Yu An,et al.  Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[182]  M. Egger,et al.  Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials , 2002, BMJ : British Medical Journal.

[183]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[184]  G. Spinzi,et al.  A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. , 2001, Gastrointestinal endoscopy.

[185]  Michael E. Phelps,et al.  Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma , 2001 .

[186]  A. Carlin,et al.  Guidelines 2000 for colon and rectal cancer surgery. , 2001, Journal of the National Cancer Institute.

[187]  P. Valk,et al.  Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[188]  S. Dwivedi,et al.  Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer , 2001, British Journal of Cancer.

[189]  J Kotzerke,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[190]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18f]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma : Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001 .

[191]  S S Gambhir,et al.  A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[192]  E T Stewart,et al.  A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. , 2000, The New England journal of medicine.

[193]  H Nakata,et al.  Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. , 2000, AJR. American journal of roentgenology.

[194]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[195]  L. Liberman,et al.  Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. , 1999, AJR. American journal of roentgenology.

[196]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[197]  L. Liberman,et al.  The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. , 1998, AJR. American journal of roentgenology.

[198]  W. P. Evans,et al.  Stereotactic Core‐Needle Biopsy of the Breast: A Report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists , 1997, CA: a cancer journal for clinicians.

[199]  E G Hahn,et al.  Invasive carcinoma in colorectal adenomas: multivariate analysis of patient and adenoma characteristics. , 1997, Endoscopy.

[200]  D. Dershaw,et al.  Mammography in patients with breast cancer treated by breast conservation (lumpectomy with or without radiation) , 1995, AJR. American journal of roentgenology.

[201]  P. Templeton,et al.  Bronchogenic carcinoma: radiologic-pathologic correlation. , 1994 .

[202]  J. Ophir,et al.  Elastography: A Quantitative Method for Imaging the Elasticity of Biological Tissues , 1991 .

[203]  C. Copie-Bergman,et al.  Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[204]  W. P. Evans,et al.  Breast cancer screening: Successes and challenges , 2012, CA: a cancer journal for clinicians.

[205]  Woo Kyung Moon,et al.  Distinguishing benign from malignant masses at breast US: combined US elastography and color doppler US--influence on radiologist accuracy. , 2012, Radiology.

[206]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[207]  L. Tanoue,et al.  Reduced lung cancer mortality with low-dose computed tomographic screening , 2011 .

[208]  Karen Wong,et al.  Positron emission tomography and colorectal cancer. , 2011, Critical reviews in oncology/hematology.

[209]  R. Oyen,et al.  6. 3 Tesla whole-body diffusion-weighted imaging (WB-DWI) for early treatment assessment and treatment prediction in lymphoma , 2011 .

[210]  D. Lynch,et al.  The National Lung Screening Trial: overview and study design. , 2011, Radiology.

[211]  A. Nagler,et al.  Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[212]  C. D'Orsi,et al.  Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. , 2010, Journal of the American College of Radiology : JACR.

[213]  V. Ambrosini,et al.  Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[214]  I. Lossos,et al.  High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[215]  A. Gillams,et al.  Imaging appearances following thermal ablation. , 2008, Clinical radiology.

[216]  R. Hicks,et al.  FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY ON STAGING AND MANAGEMENT OF EARLY-STAGE FOLLICULAR NON-HODGKIN LYMPHOMA , 2022 .

[217]  R. Birdwell.  Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study , 2008 .

[218]  G. Antoch,et al.  Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. , 2008, European journal of radiology.

[219]  F DuBois Bowman,et al.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[220]  Suman Jana,et al.  Nuclear medicine studies of the prostate, testes, and bladder. , 2006, Seminars in nuclear medicine.

[221]  T. Hany,et al.  Bone involvement in patients with lymphoma: the role of FDG-PET/CT , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[222]  Z. Lengyel,et al.  Detection of prostate cancer with 11C-methionine positron emission tomography. , 2005, The Journal of urology.

[223]  Y. Erdi,et al.  Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[224]  R. Hustinx,et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[225]  A. Koong,et al.  Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. , 2003, International journal of radiation oncology, biology, physics.

[226]  Michael Pignone,et al.  Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. , 2002, Annals of internal medicine.

[227]  B. Krug,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease , 2001, Annals of Hematology.

[228]  B. Beuthien-Baumann,et al.  Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 2001, British journal of haematology.

[229]  P. Valk,et al.  Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[230]  L. Schwartz,et al.  Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. , 2000, Radiology.

[231]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.

[232]  C. Boetes,et al.  False-negative MR imaging of malignant breast tumors , 1997, European Radiology.

[233]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[234]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.

[235]  N. Dubrawsky.  Cancer statistics , 2022 .